Komori
Other Disclosures4579RaQualia Pharma Inc.Pharmaceuticals

Notice Regarding the Publication of an Analyst Report on Our Company by 株式会社エンヴァリス

株式会社エンヴァリス published an analyst report analyzing RaQualia Pharma Inc.'s results for the second quarter of the fiscal year ending December 2026. The Company is providing investors with information on where to view the report.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

Analyst report
Applicable field (uses covered by this announcement)

Research and analysis of the Company's business, financial position and medium- to long-term growth potential

Launch date19 August 2026 (already published)
Relationship between the counterparty and the company
RaQualia Pharma Inc.4579
Relationship with the Company

株式会社エンヴァリス prepared the analyst report at the Company's request.

Counterparty株式会社エンヴァリス

Independent research firm

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

株式会社エンヴァリス official website (https://envalith.com/ja/companies/4579)

Announced details
ItemDetails
Names of Products / Services CoveredAnalyst report
Counterparty株式会社エンヴァリス
Counterparty overviewIndependent research firm
Relationship with the Company株式会社エンヴァリス prepared the analyst report at the Company's request.
Launch date19 August 2026 (already published)
Applicable areaResearch and analysis of the Company's business, financial position and medium- to long-term growth potential
Source株式会社エンヴァリス official website (https://envalith.com/ja/companies/4579)
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company determined that the report would serve as a useful source of information for domestic and overseas institutional investors and individual investors to deepen their understanding of the Company's business, financial position and medium- to long-term growth potential, and to assist them in making investment decisions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Publication of an Analyst Report on Our Company by 株式会社エンヴァリス | RaQualia Pharma Inc. (4579) timely disclosure | Komori